---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029249"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-05T00:08:17.317255+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics reports FY2023 net loss $66.4M, raises $95M in private placement, extends runway into 2027

## Summary
- Net loss $66.4M for 2023 ($12.40/share) vs $59.3M in 2022; cash $121.5M at year-end.
- $95M private placement at $15.13/share; co-led by Braidwell and Adage Capital; expected close March 13.
- LX2006 Cohort 2 shows positive frataxin increase; interim data from SUNRISE-FA expected mid-2024.
- LX2020 granted FDA Fast Track and Orphan Drug Designation; first patient dosing expected in 1H 2024.
- Cash runway extended to fund operations into 2027.

## SEC filing metadata
- accession: 0000950170-24-029249
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/0000950170-24-029249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/lxeo-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029249
- JSON: https://secwatch.observer/filing/0000950170-24-029249.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029249.txt

## Key facts
- Earnings Releases
  Lexeo Therapeutics, Inc. reported financial results for fourth quarter and full year 2023.
  - Period: fourth quarter and full year 2023
  - Result: reported results
  source text: On March 11, 2024, the Company issued a press release announcing business highlights and its financial results for the three and twelve-months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/0000950170-24-029249-index.htm
- Material Agreements
  Lexeo Therapeutics, Inc. entered into Common Stock Purchase Agreement with certain qualified institutional buyers and institutional accredited investors valued at approximately $95 million (effective 2024-03-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain qualified institutional buyers and institutional accredited investors
  - Value: approximately $95 million
  - Effective: 2024-03-11
  source text: On March 11, 2024, Lexeo Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain qualified institutional buyers and institutional accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907108/000095017024029249/0000950170-24-029249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.